The turnaround at Teva Pharmaceutical Industries (TEVA) remains on schedule. Investors appear satisfied that CEO Kare Schultz is making enough progress in battling …
Teva (TEVA) stock’s chart for the past few months looks like nothing short of a roller-coaster ride. Shares of the Israeli drug giant …
Israeli generic drug manufacturer Teva (TEVA) was named by the Washington Post as being one of more than a dozen subjects of a …
Borrowing heavily to become a leading generic drug company just as generic drug prices began tanking has been a drag on Teva Pharmaceutical (TEVA). …
There’s a new FDA-approved migraine treatment on the scene. On Friday night, the U.
Teva’s (NYSE:TEVA) honeymoon with Wall Street hit a big bump on Thursday, when the Israel-based generics giant reported mixed second-quarter results. Teva reported …
Guggenheim’s Rohit Vanjani is not fazed by the updated PDUFA date for Teva’s fremanezumab- as long as the Celtrion facility re-inspection goes off without a hitch,
Though Teva served up a strong first quarter for 2018, BTIG’s Tim Chiang continues to make a bearish case on this challenged Israeli pharma giant.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced the launch of a generic version of ALOXI®1 (palonosetron HCI) injection, 0.25 mg/5 mL, in the United States.
David Steinberg is out with a cautious note on Teva, believing much of the outlook is priced into the stock.
